1887

Chapter 109 : Mechanisms of Resistance to Antiviral Agents

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Zoom in
Zoomout

Mechanisms of Resistance to Antiviral Agents , Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555816728/9781555814632_Chap109-1.gif /docserver/preview/fulltext/10.1128/9781555816728/9781555814632_Chap109-2.gif

Abstract:

Understanding the mechanisms of viral drug resistance is critical to the clinical management of individuals receiving antiviral therapy, the development of new antiviral drugs, and the surveillance of drug resistance. This chapter reviews the mechanisms of resistance to antiviral agents used to treat seven common viral infections, i.e., infections with herpes simplex virus (HSV), cytomegalovirus (CMV), varicella-zoster virus (VZV), human immunodeficiency virus types 1 and 2 (HIV-1 and HIV-2), influenza A and B viruses, hepatitis B virus (HBV), and hepatitis C virus (HCV). Antiviral drug resistance is usually mediated by mutations in the molecular targets of drug therapy, and the development of drug resistance is the most compelling evidence that an antiviral drug acts by specifically inhibiting a virus rather than its cellular host. Drug-resistant viruses are identified by in vitro passage experiments with increasing concentrations of an inhibitory drug and by ex vivo analysis of virus isolates obtained from individuals receiving antiviral therapy. Antiviral agents, mechanisms of resistance, and mutations involved in drug resistance in herpesviruses are summarized in a tabular form. Most TK mutants are classified as TK negative, usually arising from frameshift or stop mutations that delete important functional domains, or TK partial, when a mutation reduces the phosphorylation of both natural nucleosides and antiviral drugs. Nucleoside analog RdRp inhibitors appear to be equally active against the different HCV genotypes. The genetic barrier to nucleoside analog resistance also appears to be higher than that for the other two main classes of HCV inhibitors.

Citation: Shafer R, Najera I, Chou S. 2011. Mechanisms of Resistance to Antiviral Agents , p 1710-1728. In Versalovic J, Carroll K, Funke G, Jorgensen J, Landry M, Warnock D (ed), Manual of Clinical Microbiology, 10th Edition. ASM Press, Washington, DC. doi: 10.1128/9781555816728.ch109

Key Concept Ranking

Human immunodeficiency virus 1
0.5185635
0.5185635
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

References

/content/book/10.1128/9781555816728.chap109
1. Abdel-Ghafar, A. N.,, T. Chotpitayasunondh,, Z. Gao,, F. G. Hayden,, D. H. Nguyen,, M. D. de Jong,, A. Naghdaliyev,, J. S. Peiris,, N. Shindo,, S. Soeroso,, and T. M. Uyeki. 2008. Update on avian influenza A (H5N1) virus infection in humans. N. Engl. J. Med. 358:261273.
2. Abed, Y.,, M. Baz,, and G. Boivin. 2006. Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds. Antivir. Ther. 11:971976.
3. Ali, S.,, V. Leveque,, S. Le Pogam,, H. Ma,, F. Philipp,, N. Inocencio,, M. Smith,, A. Alker,, H. Kang,, I. Najera,, K. Klumpp,, J. Symons,, N. Cammack,, and W. R. Jiang. 2008. Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor PSI- 6130 lack cross-resistance with R1479. Antimicrob. Agents Chemother. 52:43564369.
4. Alian, A.,, S. L. Griner,, V. Chiang,, M. Tsiang,, G. Jones,, G. Birkus,, R. Geleziunas,, A. D. Leavitt,, and R. M. Stroud. 2009. Catalytically-active complex of HIV-1 integrase with a viral DNA substrate binds anti-integrase drugs. Proc. Natl. Acad. Sci. USA 106:81928197.
5. Allen, M. I.,, M. Deslauriers,, C. W. Andrews,, G. A. Tipples,, K. A. Walters,, D. L. Tyrrell,, N. Brown,, and L. D. Condreay. 1998. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 27:16701677.
6. Andrei, G.,, E. De Clercq,, and R. Snoeck. 2008. Novel inhibitors of human CMV. Curr. Opin. Investig. Drugs 9:132145.
7. Angus, P.,, R. Vaughan,, S. Xiong,, H. Yang,, W. Delaney,, C. Gibbs,, C. Brosgart,, D. Colledge,, R. Edwards,, A. Ayres,, A. Bartholomeusz,, and S. Locarnini. 2003. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 125:292297.
8. Arion, D.,, N. Sluis-Cremer,, and M. A. Parniak. 2000. Mechanism by which phosphonoformic acid resistance mutations restore 3'-azido-3'-deoxythymidine (AZT) sensitivity to AZT-resistant HIV-1 reverse transcriptase. J. Biol. Chem. 275:92519255.
9. Bartels, D. J.,, Y. Zhou,, E. Z. Zhang,, M. Marcial,, R. A. Byrn,, T. Pfeiffer,, A. M. Tigges,, B. S. Adiwijaya,, C. Lin,, A. D. Kwong,, and T. L. Kieffer. 2008. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects. J. Infect. Dis. 198:800807.
10. Bartholomeusz, A.,, B. G. Tehan,, and D. K. Chalmers. 2004. Comparisons of the HBV and HIV polymerase, and antiviral resistance mutations. Antivir. Ther. 9:149160.
11. Belshe, R. B.,, B. Burk,, F. Newman,, R. L. Cerruti,, and I. S. Sim. 1989. Resistance of influenza A virus to amantadine and rimantadine: results of one decade of surveillance. J. Infect. Dis. 159:430435.
12. Belshe, R. B.,, M. H. Smith,, C. B. Hall,, R. Betts,, and A. J. Hay. 1988. Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection. J. Virol. 62:15081512.
13. Berman, K.,, and P. Y. Kwo. 2009. Boceprevir, an NS3 protease inhibitor of HCV. Clin. Liver Dis. 13:429439.
14. Bestman-Smith, J.,, and G. Boivin. 2003. Drug resistance patterns of recombinant herpes simplex virus DNA polymerase mutants generated with a set of overlapping cosmids and plasmids. J. Virol. 77:78207829.
15. Bierman, W. F.,, M. A. van Agtmael,, M. Nijhuis,, S. A. Danner,, and C. A. Boucher. 2009. HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review. AIDS 23:279291.
16. Biron, K. K.,, R. J. Harvey,, S. C. Chamberlain,, S. S. Good,, A. A. Smith III,, M. G. Davis,, C. L. Talarico,, W. H. Miller,, R. Ferris,, R. E. Dornsife,, S. C. Stanat,, J. C. Drach,, L. B. Townsend,, and G. W. Koszalka. 2002. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole l-riboside with a unique mode of action. Antimicrob. Agents Chemother. 46:23652372.
17. Boltz, D. A.,, B. Douangngeun,, P. Phommachanh,, S. Sinthasak,, R. Mondry,, C. A. Obert,, P. Seiler,, R. Keating,, Y. Suzuki,, H. Hiramatsu,, E. Govorkova,, and R. G. Webster. 2010. Emergence of H5N1 avian influenza viruses with reduced sensitivity to neuraminidase inhibitors and novel reassortants in Lao People’s Democratic Republic. J. Gen. Virol. 91:949959.
18. Borroto-Esoda, K.,, M. D. Miller,, and S. Arterburn. 2007. Pooled analysis of amino acid changes in the HBV polymerase in patients from four major adefovir dipivoxil clinical trials. J. Hepatol. 47:492498.
19. Brenner, B.,, D. Turner,, M. Oliveira,, D. Moisi,, M. Detorio,, M. Carobene,, R. G. Marlink,, J. Schapiro,, M. Roger,, and M. A. Wainberg. 2003. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to nonnucleoside reverse transcriptase inhibitors. AIDS 17:F1F5.
20. Bright, R. A.,, M. J. Medina,, X. Xu,, G. Perez-Oronoz,, T. R. Wallis,, X. M. Davis,, L. Povinelli,, N. J. Cox,, and A. I. Klimov. 2005. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 366:11751181.
21. Bright, R. A.,, D. K. Shay,, B. Shu,, N. J. Cox,, and A. I. Klimov. 2006. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 295:891894.
22. Bryan, C. J.,, M. N. Prichard,, S. Daily,, G. Jefferson,, C. Hartline,, K. A. Cassady,, L. Hilliard,, and M. Shimamura. 2008. Acyclovir-resistant chronic verrucous vaccine strain varicella in a patient with neuroblastoma. Pediatr. Infect. Dis. J. 27:946948.
23. Burton, J. R., Jr.,, and G. T. Everson. 2009. HCV NS5B polymerase inhibitors. Clin. Liver Dis. 13:453465.
24. Buti, M.,, F. Rodriguez-Frias,, R. Jardi,, and R. Esteban. 2005. Hepatitis B virus genome variability and disease progression: the impact of pre-core mutants and HBV genotypes. J. Clin. Virol. 34(Suppl. 1):S79S82.
25. Cady, S. D.,, W. Luo,, F. Hu,, and M. Hong. 2009. Structure and function of the influenza A M2 proton channel. Biochemistry 48:73567364.
26. Camacho, R.,, A. Godinho,, P. Gomes,, A. Abecasis,, A.-M. Vandamme,, C. Palma,, A. P. Carvalho,, J. Cabanas,, and J. Goncalves. 2005. Different substitutions under drug pressure at protease codon 82 in HIV-1 subtype G compared to subtype B infected individuals including a novel I82M resistance mutations. Antivir. Ther. 10:S151.
27. Cane, P. A.,, A. de Ruiter,, P. Rice,, M. Wiselka,, R. Fox,, and D. Pillay. 2001. Resistance-associated mutations in the human immunodeficiency virus type 1 subtype C protease gene from treated and untreated patients in the United Kingdom. J. Clin. Microbiol. 39:26522654.
28.Centers for Disease Control and Prevention. 2009. Oseltamivir- resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis—North Carolina, 2009. MMWR Morb. Mortal. Wkly. Rep. 58:969972.
29.Centers for Disease Control and Prevention. 2009. Update: drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009. MMWR Morb. Mortal. Wkly. Rep. 58:433435.
30. Chan, P.,, and R. Kantor. 2009. Transmitted drug resistance in nonsubtype B HIV-1 infection. HIV Ther. 3:447465.
31. Chen, J. C.,, J. Krucinski,, L. J. Miercke,, J. S. Finer-Moore,, A. H. Tang,, A. D. Leavitt,, and R. M. Stroud. 2000. Crystal structure of the HIV-1 integrase catalytic core and C-terminal domains: a model for viral DNA binding. Proc. Natl. Acad. Sci. USA 97:82338238.
32. Chen, S. H.,, A. Pearson,, D. M. Coen,, and S. H. Chen. 2004. Failure of thymidine kinase-negative herpes simplex virus to reactivate from latency following efficient establishment. J. Virol. 78:520523.
33. Chen, X.,, M. Tsiang,, F. Yu,, M. Hung,, G. S. Jones,, A. Zeynalzadegan,, X. Qi,, H. Jin,, C. U. Kim,, S. Swaminathan,, and J. M. Chen. 2008. Modeling, analysis, and validation of a novel HIV integrase structure provide insights into the binding modes of potent integrase inhibitors. J. Mol. Biol. 380:504519.
34. Cheung, C. L.,, J. M. Rayner,, G. J. Smith,, P. Wang,, T. S. Naipospos,, J. Zhang,, K. Y. Yuen,, R. G. Webster,, J. S. Peiris,, Y. Guan,, and H. Chen. 2006. Distribution of amantadine-resistant H5N1 avian influenza variants in Asia. J. Infect. Dis. 193:16261629.
35. Chevaliez, S.,, R. Brillet,, E. Lazaro,, C. Hezode,, and J. M. Pawlotsky. 2007. Analysis of ribavirin mutagenicity in human hepatitis C virus infection. J. Virol. 81:77327741.
36. Choe, W. H.,, S. P. Hong,, B. K. Kim,, S. Y. Ko,, Y. K. Jung,, J. H. Kim,, J. E. Yeon,, K. S. Byun,, K. H. Kim,, S. I. Ji,, S. O. Kim,, C. H. Lee,, and S. Y. Kwon. 2009. Evolution of hepatitis B virus mutation during entecavir rescue therapy in patients with antiviral resistance to lamivudine and adefovir. Antivir. Ther. 14:985993.
37. Chou, S. 2008. Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir. Rev. Med. Virol. 18:233246.
38. Chou, S. 2009. Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir. Antimicrob. Agents Chemother. 53:8185.
39. Chou, S.,, N. S. Lurain,, K. D. Thompson,, R. C. Miner,, and W. L. Drew. 2003. Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. J. Infect. Dis. 188:3239.
40. Chou, S.,, G. Marousek,, S. Guentzel,, S. E. Follansbee,, M. E. Poscher,, J. P. Lalezari,, R. C. Miner,, and W. L. Drew. 1997. Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. J. Infect. Dis. 176:786789.
41. Chou, S.,, G. I. Marousek,, L. C. Van Wechel,, S. Li,, and A. Weinberg. 2007. Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens. Antimicrob. Agents Chemother. 51:41604162.
42. Chou, S.,, L. C. Van Wechel,, H. M. Lichy,, and G. I. Marousek. 2005. Phenotyping of cytomegalovirus drug resistance mutations by using recombinant viruses incorporating a reporter gene. Antimicrob. Agents Chemother. 49: 27102715.
43. Coffin, J. M. 1995. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267:483489.
44. Cohen, J. I.,, P. A. Brunell,, S. E. Straus,, and P. R. Krause. 1999. Recent advances in varicella-zoster virus infection. Ann. Intern. Med. 130:922932.
45. Collins, P. J.,, L. F. Haire,, Y. P. Lin,, J. Liu,, R. J. Russell,, P. A. Walker,, S. R. Martin,, R. S. Daniels,, V. Gregory,, J. J. Skehel,, S. J. Gamblin,, and A. J. Hay. 2009. Structural basis for oseltamivir resistance of influenza viruses. Vaccine 27:63176323.
46. Collins, P. J.,, L. F. Haire,, Y. P. Lin,, J. Liu,, R. J. Russell,, P. A. Walker,, J. J. Skehel,, S. R. Martin,, A. J. Hay,, and S. J. Gamblin. 2008. Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants. Nature 453:12581261.
47. Colman, P. M. 1994. Influenza virus neuraminidase: structure, antibodies, and inhibitors. Protein Sci. 3:16871696.
48. Colman, P. M.,, P. A. Hoyne,, and M. C. Lawrence. 1993. Sequence and structure alignment of paramyxovirus hemagglutinin- neuraminidase with influenza virus neuraminidase. J. Virol. 67:29722980.
49. Cote, H. C.,, Z. L. Brumme,, and P. R. Harrigan. 2001. Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir. J. Virol. 75:589594.
50. Crotty, S.,, D. Maag,, J. J. Arnold,, W. Zhong,, J. Y. Lau,, Z. Hong,, R. Andino,, and C. E. Cameron. 2000. The broadspectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat. Med. 6:13751379.
51. Das, K.,, A. D. Clark, Jr.,, P. J. Lewi,, J. Heeres,, M. R. De Jonge,, L. M. Koymans,, H. M. Vinkers,, F. Daeyaert,, D. W. Ludovici,, M. J. Kukla,, B. De Corte,, R. W. Kavash,, C. Y. Ho,, H. Ye,, M. A. Lichtenstein,, K. Andries,, R. Pauwels,, M. P. De Bethune,, P. L. Boyer,, P. Clark,, S. H. Hughes,, P. A. Janssen,, and E. Arnold. 2004. Roles of conformational and positional adaptability in structure-based design of TMC125- R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J. Med. Chem. 47:25502560.
52. Das, K.,, X. Xiong,, H. Yang,, C. E. Westland,, C. S. Gibbs,, S. G. Sarafianos,, and E. Arnold. 2001. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine and emtricitabine. J. Virol. 75:47714779.
53. Dawood, F. S.,, S. Jain,, L. Finelli,, M. W. Shaw,, S. Lindstrom,, R. J. Garten,, L. V. Gubareva,, X. Xu,, C. B. Bridges,, and T. M. Uyeki. 2009. Emergence of a novel swineorigin influenza A (H1N1) virus in humans. N. Engl. J. Med. 360:26052615.
54. de Jong, M. D.,, T. T. Tran,, H. K. Truong,, M. H. Vo,, G. J. Smith,, V. C. Nguyen,, V. C. Bach,, T. Q. Phan,, Q. H. Do,, Y. Guan,, J. S. Peiris,, T. H. Tran,, and J. Farrar. 2005. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N. Engl. J. Med. 353:26672672.
55. Delaney, W. E., IV,, H. Yang,, C. E. Westland,, K. Das,, E. Arnold,, C. S. Gibbs,, M. D. Miller,, and S. Xiong. 2003. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J. Virol. 77:1183311841.
56. De Meyer, S.,, H. Azijn,, D. Surleraux,, D. Jochmans,, A. Tahri,, R. Pauwels,, P. Wigerinck,, and M. P. de Bethune. 2005. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob. Agents Chemother. 49:23142321.
57. Deyde, V. M.,, T. G. Sheu,, A. A. Trujillo,, M. Okomo- Adhiambo,, R. Garten,, A. I. Klimov,, and L. V. Gubareva. 2010. Detection of molecular markers of drug resistance in the 2009 pandemic influenza A (H1N1) viruses using pyrosequencing. Antimicrob. Agents Chemother. 54:11021110.
58. Dharan, N. J.,, L. V. Gubareva,, J. J. Meyer,, M. Okomo- Adhiambo,, R. C. McClinton,, S. A. Marshall,, K. St. George,, S. Epperson,, L. Brammer,, A. I. Klimov,, J. S. Bresee,, and A. M. Fry. 2009. Infections with oseltamivir-resistant influenza A (H1N1) virus in the United States. JAMA 301:10341041.
59. Dorr, P.,, M. Westby,, S. Dobbs,, P. Griffin,, B. Irvine,, M. Macartney,, J. Mori,, G. Rickett,, C. Smith-Burchnell,, C. Napier,, R. Webster,, D. Armour,, D. Price,, B. Stammen,, A. Wood,, and M. Perros. 2005. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 49:47214732.
60. Duan, R.,, R. D. de Vries,, A. D. Osterhaus,, L. Remeijer,, and G. M. Verjans. 2008. Acyclovir-resistant corneal HSV-1 isolates from patients with herpetic keratitis. J. Infect. Dis. 198:659663.
61. Enomoto, N.,, I. Sakuma,, Y. Asahina,, M. Kurosaki,, T. Murakami,, C. Yamamoto,, Y. Ogura,, N. Izumi,, F. Marumo,, and C. Sato. 1996. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N. Engl. J. Med. 334:7781.
62. Erice, A.,, C. Gil-Roda,, J. L. Perez,, H. H. Balfour, Jr.,, K. J. Sannerud,, M. N. Hanson,, G. Boivin,, and S. Chou. 1997. Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. J. Infect. Dis. 175:10871092.
63. Erickson, J. W.,, S. V. Gulnik,, and M. Markowitz. 1999. Protease inhibitors: resistance, cross-resistance, fitness and the choice of initial and salvage therapies. AIDS 13(Suppl. A):S189S204.
64. Farci, P.,, R. Strazzera,, H. J. Alter,, S. Farci,, D. Degioannis,, A. Coiana,, G. Peddis,, F. Usai,, G. Serra,, L. Chessa,, G. Diaz,, A. Balestrieri,, and R. H. Purcell. 2002. Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. Proc. Natl. Acad. Sci. USA 99:30813086.
65. Fransen, S.,, M. Karmochkine,, W. Huang,, L. Weiss,, C. J. Petropoulos,, and C. Charpentier. 2009. Longitudinal analysis of raltegravir susceptibility and integrase replication capacity of HIV-1 during virologic failure. Antimicrob. Agents Chemother. 53:45224524.
66. Frobert, E.,, J. C. Cortay,, T. Ooka,, F. Najioullah,, D. Thouvenot,, B. Lina,, and F. Morfin. 2008. Genotypic detection of acyclovir-resistant HSV-1: characterization of 67 ACVsensitive and 14 ACV-resistant viruses. Antivir. Res. 79:2836.
67. Frobert, E.,, T. Ooka,, J. C. Cortay,, B. Lina,, D. Thouvenot,, and F. Morfin. 2005. Herpes simplex virus thymidine kinase mutations associated with resistance to acyclovir: a site-directed mutagenesis study. Antimicrob. Agents Chemother. 49:10551059.
68. Fung, S. K.,, H. B. Chae,, R. J. Fontana,, H. Conjeevaram,, J. Marrero,, K. Oberhelman,, M. Hussain,, and A. S. Lok. 2006. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J. Hepatol. 44:283290.
69. Furuse, Y.,, A. Suzuki,, and H. Oshitani. 2009. Large-scale sequence analysis of M gene of influenza A viruses from different species: mechanisms for emergence and spread of amantadine resistance. Antimicrob. Agents Chemother. 53:44574463.
70. Gale, M., Jr.,, and E. M. Foy. 2005. Evasion of intracellular host defence by hepatitis C virus. Nature 436:939945.
71. Ganem, D.,, and A. M. Prince. 2004. Hepatitis B virus infection— natural history and clinical consequences. N. Engl. J. Med. 350:11181129.
72. Garten, R. J.,, C. T. Davis,, C. A. Russell,, B. Shu,, S. Lindstrom,, A. Balish,, W. M. Sessions,, X. Xu,, E. Skepner,, V. Deyde,, M. Okomo-Adhiambo,, L. Gubareva,, J. Barnes,, C. B. Smith,, S. L. Emery,, M. J. Hillman,, P. Rivailler,, J. Smagala,, M. de Graaf,, D. F. Burke,, R. A. Fouchier,, C. Pappas,, C. M. Alpuche-Aranda,, H. Lopez-Gatell,, H. Olivera,, I. Lopez,, C. A. Myers,, D. Faix,, P. J. Blair,, C. Yu,, K. M. Keene,, P. D. Dotson, Jr.,, D. Boxrud,, A. R. Sambol,, S. H. Abid,, K. St. George,, T. Bannerman,, A. L. Moore,, D. J. Stringer,, P. Blevins,, G. J. Demmler-Harrison,, M. Ginsberg,, P. Kriner,, S. Waterman,, S. Smole,, H. F. Guevara,, E. A. Belongia,, P. A. Clark,, S. T. Beatrice,, R. Donis,, J. Katz,, L. Finelli,, C. B. Bridges,, M. Shaw,, D. B. Jernigan,, T. M. Uyeki,, D. J. Smith,, A. I. Klimov,, and N. J. Cox. 2009. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 325:197201.
73. Geretti, A. M. 2007. Epidemiology of antiretroviral drug resistance in drug-naive persons. Curr. Opin. Infect. Dis. 20:2232.
74. Ghany, M. G.,, D. B. Strader,, D. L. Thomas,, and L. B. Seeff. 2009. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 49:13351374.
75. Gilbert, C.,, J. Bestman-Smith,, and G. Boivin. 2002. Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms. Drug Resist. Updat. 5:88114.
76. Gilbert, C.,, and G. Boivin. 2005. Human cytomegalovirus resistance to antiviral drugs. Antimicrob. Agents Chemother. 49:873883.
77. Goldgur, Y.,, R. Craigie,, G. H. Cohen,, T. Fujiwara,, T. Yoshinaga,, T. Fujishita,, H. Sugimoto,, T. Endo,, H. Murai,, and D. R. Davies. 1999. Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design. Proc. Natl. Acad. Sci. USA 96:1304013043.
78. Gooskens, J.,, M. Jonges,, E. C. Claas,, A. Meijer,, P. J. van den Broek,, and A. M. Kroes. 2009. Morbidity and mortality associated with nosocomial transmission of oseltamivirresistant influenza A(H1N1) virus. JAMA 301:10421046.
79. Grambas, S.,, M. S. Bennett,, and A. J. Hay. 1992. Influence of amantadine resistance mutations on the pH regulatory function of the M2 protein of influenza A viruses. Virology 191:541549.
80. Grey, F.,, M. Sowa,, P. Collins,, R. J. Fenton,, W. Harris,, W. Snowden,, S. Efstathiou,, and G. Darby. 2003. Characterization of a neurovirulent aciclovir-resistant variant of herpes simplex virus. J. Gen. Virol. 84:14031410.
81. Griffiths, A.,, M. A. Link,, C. L. Furness,, and D. M. Coen. 2006. Low-level expression and reversion both contribute to reactivation of herpes simplex virus drug-resistant mutants with mutations on homopolymeric sequences in thymidine kinase. J. Virol. 80:65686574.
82. Grossman, Z.,, V. Istomin,, D. Averbuch,, M. Lorber,, K. Risenberg,, I. Levi,, M. Chowers,, M. Burke,, N. Bar Yaacov,, and J. M. Schapiro. 2004. Genetic variation at NNRTI resistance- associated positions in patients infected with HIV-1 subtype C. AIDS 18:909915.
83. Gubareva, L. V. 2004. Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors. Virus Res. 103:199203.
84. Gubareva, L. V.,, L. Kaiser,, and F. G. Hayden. 2000. Influenza virus neuraminidase inhibitors. Lancet 355:827835.
85. Gubareva, L. V.,, L. Kaiser,, M. N. Matrosovich,, Y. Soo-Hoo,, and F. G. Hayden. 2001. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J. Infect. Dis. 183:523531.
86. Gubareva, L. V.,, M. N. Matrosovich,, M. K. Brenner,, R. C. Bethell,, and R. G. Webster. 1998. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J. Infect. Dis. 178:12571262.
87. Gunther, S.,, L. Fischer,, I. Pult,, M. Sterneck,, and H. Will. 1999. Naturally occurring variants of hepatitis B virus. Adv. Virus Res. 52:25137.
88. Hadziyannis, S. J.,, N. C. Tassopoulos,, E. J. Heathcote,, T. T. Chang,, G. Kitis,, M. Rizzetto,, P. Marcellin,, S. G. Lim,, Z. Goodman,, J. Ma,, C. L. Brosgart,, K. Borroto-Esoda,, S. Arterburn,, and S. L. Chuck. 2006. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 131:17431751.
89. Hartley, O.,, P. Klasse,, Q. Sattentau,, and J. P. Moore. 2005. V3: HIV’s switch hitter. AIDS Res. Hum. Retrovir. 21:171189.
90. Hatchette, T.,, G. A. Tipples,, G. Peters,, A. Alsuwaidi,, J. Zhou,, and T. L. Mailman. 2008. Foscarnet salvage therapy for acyclovir-resistant varicella zoster: report of a novel thymidine kinase mutation and review of the literature. Pediatr. Infect. Dis. J. 27:7577.
91. Hayden, F. G.,, R. B. Belshe,, R. D. Clover,, A. J. Hay,, M. G. Oakes,, and W. Soo. 1989. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N. Engl. J. Med. 321:16961702.
92. Hezode, C.,, N. Forestier,, G. Dusheiko,, P. Ferenci,, S. Pol,, T. Goeser,, J. P. Bronowicki,, M. Bourliere,, S. Gharakhanian,, L. Bengtsson,, L. McNair,, S. George,, T. Kieffer,, A. Kwong,, R. S. Kauffman,, J. Alam,, J. M. Pawlotsky,, and S. Zeuzem. 2009. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N. Engl. J. Med. 360:18391850.
93. Hicks, C. B.,, P. Cahn,, D. A. Cooper,, S. L. Walmsley,, C. Katlama,, B. Clotet,, A. Lazzarin,, M. A. Johnson,, D. Neubacher,, D. Mayers,, and H. Valdez. 2006. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatmentexperienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in Multi- Drug Resistant Patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet 368:466475.
94. Hirsch, M. S.,, H. F. Gunthard,, J. M. Schapiro,, F. Brun- Vezinet,, B. Clotet,, S. M. Hammer,, V. A. Johnson,, D. R. Kuritzkes,, J. W. Mellors,, D. Pillay,, P. G. Yeni,, D. M. Jacobsen,, and D. D. Richman. 2008. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin. Infect. Dis. 47:266285.
95. Hosseinipour, M. C.,, J. J. van Oosterhout,, R. Weigel,, S. Phiri,, D. Kamwendo,, N. Parkin,, S. A. Fiscus,, J. A. Nelson,, J. J. Eron,, and J. Kumwenda. 2009. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS 23:11271134.
96. Hurt, A. C.,, J. K. Holien,, and I. G. Barr. 2009. In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. Antimicrob. Agents Chemother. 53:44334440.
97. Hurt, A. C.,, J. K. Holien,, M. Parker,, A. Kelso,, and I. G. Barr. 2009. Zanamivir-resistant influenza viruses with a novel neuraminidase mutation. J. Virol. 83:1036610373.
98. Invernizzi, C. F.,, D. Coutsinos,, M. Oliveira,, D. Moisi,, B. G. Brenner,, and M. A. Wainberg. 2009. Signature nucleotide polymorphisms at positions 64 and 65 in reverse transcriptase favor the selection of the K65R resistance mutation in HIV-1 subtype C. J. Infect. Dis. 200:12021206.
99. Ives, J. A.,, J. A. Carr,, D. B. Mendel,, C. Y. Tai,, R. Lambkin,, L. Kelly,, J. S. Oxford,, F. G. Hayden,, and N. A. Roberts. 2002. The H274Y mutation in the influenza A/ H1N1 neuraminidase active site following oseltamivir phosphate treatment leaves virus severely compromised both in vitro and in vivo. Antivir. Res. 55:307317.
100. Kantor, R.,, D. A. Katzenstein,, B. Efron,, A. P. Carvalho,, B. Wynhoven,, P. Cane,, J. Clarke,, S. Sirivichayakul,, M. A. Soares,, J. Snoeck,, C. Pillay,, H. Rudich,, R. Rodrigues,, A. Holguin,, K. Ariyoshi,, M. B. Bouzas,, P. Cahn,, W. Sugiura,, V. Soriano,, L. F. Brigido,, Z. Grossman,, L. Morris,, A. M. Vandamme,, A. Tanuri,, P. Phanuphak,, J. N. Weber,, D. Pillay,, P. R. Harrigan,, R. Camacho,, J. M. Schapiro,, and R. W. Shafer. 2005. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med. 2:e112.
101. Keeffe, E. B.,, D. T. Dieterich,, S. H. Han,, I. M. Jacobson,, P. Martin,, E. R. Schiff,, and H. Tobias. 2008. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin. Gastroenterol. Hepatol. 6:13151341.
102. Keeffe, E. B.,, D. T. Dieterich,, J. M. Pawlotsky,, and Y. Benhamou. 2008. Chronic hepatitis B: preventing, detecting, and managing viral resistance. Clin. Gastroenterol. Hepatol. 6:268274.
103. Kempf, D. J.,, J. D. Isaacson,, M. S. King,, S. C. Brun,, Y. Xu,, K. Real,, B. M. Bernstein,, A. J. Japour,, E. Sun,, and R. A. Rode. 2001. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. J. Virol. 75:74627469.
104. Kieffer, T. L.,, A. D. Kwong,, and G. R. Picchio. 2010. Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs). J. Antimicrob. Chemother. 65:202212.
105. Kieffer, T. L.,, C. Sarrazin,, J. S. Miller,, M. W. Welker,, N. Forestier,, H. W. Reesink,, A. D. Kwong,, and S. Zeuzem. 2007. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 46:631639.
106. Kilby, J. M.,, and J. J. Eron. 2003. Novel therapies based on mechanisms of HIV-1 cell entry. N. Engl. J. Med. 348: 22282238.
107. Kiso, M.,, K. Mitamura,, Y. Sakai-Tagawa,, K. Shiraishi,, C. Kawakami,, K. Kimura,, F. G. Hayden,, N. Sugaya,, and Y. Kawaoka. 2004. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 364:759765.
108. Kolli, M.,, S. Lastere,, and C. A. Schiffer. 2006. Co- evolution of nelfinavir-resistant HIV-1 protease and the p1-p6 substrate. Virology 347:405409.
109. Korber, B.,, M. Muldoon,, J. Theiler,, F. Gao,, R. Gupta,, A. Lapedes,, B. H. Hahn,, S. Wolinsky,, and T. Bhattacharya. 2000. Timing the ancestor of the HIV-1 pandemic strains. Science 288:17891796.
110. Kuntzen, T.,, J. Timm,, A. Berical,, N. Lennon,, A. M. Berlin,, S. K. Young,, B. Lee,, D. Heckerman,, J. Carlson,, L. L. Reyor,, M. Kleyman,, C. M. McMahon,, C. Birch,, J. Schulze Zur Wiesch,, T. Ledlie,, M. Koehrsen,, C. Kodira,, A. D. Roberts,, G. M. Lauer,, H. R. Rosen,, F. Bihl,, A. Cerny,, U. Spengler,, Z. Liu,, A. Y. Kim,, Y. Xing,, A. Schneidewind,, M. A. Madey,, J. F. Fleckenstein,, V. M. Park,, J. E. Galagan,, C. Nusbaum,, B. D. Walker,, G. V. Lake-Bakaar,, E. S. Daar,, I. M. Jacobson,, E. D. Gomperts,, B. R. Edlin,, S. M. Donfield,, R. T. Chung,, A. H. Talal,, T. Marion,, B. W. Birren,, M. R. Henn,, and T. M. Allen. 2008. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology 48:17691778.
111. Kuritzkes, D. R.,, C. M. Lalama,, H. J. Ribaudo,, M. Marcial,, W. A. Meyer III,, C. Shikuma,, V. A. Johnson,, S. A. Fiscus,, R. T. D’Aquila,, B. R. Schackman,, E. P. Acosta,, and R. M. Gulick. 2008. Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. J. Infect. Dis. 197:867870.
112. Kwong, A. D.,, J. L. Kim,, G. Rao,, D. Lipovsek,, and S. A. Raybuck. 1999. Hepatitis C virus NS3/4A protease. Antivir. Res. 41:6784.
113. Lai, C. L.,, J. Dienstag,, E. Schiff,, N. W. Leung,, M. Atkins,, C. Hunt,, N. Brown,, M. Woessner,, R. Boehme,, and L. Condreay. 2003. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin. Infect. Dis. 36:687696.
114. Lanier, E. R.,, M. Ait-Khaled,, J. Scott,, C. Stone,, T. Melby,, G. Sturge,, M. St. Clair,, H. Steel,, S. Hetherington,, G. Pearce,, W. Spreen,, and S. Lafon. 2004. Antiviral efficacy of abacavir in antiretroviral therapy-experienced adults harbouring HIV-1 with specific patterns of resistance to nucleoside reverse transcriptase inhibitors. Antivir. Ther. 9:3745.
115. Larder, B. A. 1994. Interactions between drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase. J. Gen. Virol. 75:951957.
116. Lau, J. Y.,, R. C. Tam,, T. J. Liang,, and Z. Hong. 2002. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 35:10021009.
117. Le, Q. M.,, M. Kiso,, K. Someya,, Y. T. Sakai,, T. H. Nguyen,, K. H. Nguyen,, N. D. Pham,, H. H. Ngyen,, S. Yamada,, Y. Muramoto,, T. Horimoto,, A. Takada,, H. Goto,, T. Suzuki,, Y. Suzuki,, and Y. Kawaoka. 2005. Avian flu: isolation of drug-resistant H5N1 virus. Nature 437:1108.
118. Leary, J. J.,, R. Wittrock,, R. T. Sarisky,, A. Weinberg,, and M. J. Levin. 2002. Susceptibilities of herpes simplex viruses to penciclovir and acyclovir in eight cell lines. Antimicrob. Agents Chemother. 46:762768.
119. Legrand-Abravanel, F.,, P. Colson,, H. Leguillou-Guillemette,, L. Alric,, I. Ravaux,, F. Lunel-Fabiani,, M. Bouviers-Alias,, P. Trimoulet,, M. L. Chaix,, C. Hezode,, J. Foucher,, H. Fontaine,, A. M. Roque-Afonso,, M. Gassin,, E. Schvoerer,, C. Gaudy,, B. Roche,, M. Doffoel,, L. D’Alteroche,, S. Vallet,, Y. Baazia,, B. Pozzetto,, V. Thibault,, J. B. Nousbaum,, D. Roulot,, H. Coppere,, T. Poinard,, C. Payan,, and J. Izopet. 2009. Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy. J. Med. Virol. 81:20292035.
120. Leneva, I. A.,, N. Roberts,, E. A. Govorkova,, O. G. Goloubeva,, and R. G. Webster. 2000. The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. Antivir. Res. 48:101115.
121. Le Pogam, S.,, W. R. Jiang,, V. Leveque,, S. Rajyaguru,, H. Ma,, H. Kang,, S. Jiang,, M. Singer,, S. Ali,, K. Klumpp,, D. Smith,, J. Symons,, N. Cammack,, and I. Najera. 2006. In vitro selected Con1 subgenomic replicons resistant to 29-C-methyl-cytidine or to R1479 show lack of cross resistance. Virology 351:349359.
122. Le Pogam, S.,, H. Kang,, S. F. Harris,, V. Leveque,, A. M. Giannetti,, S. Ali,, W. R. Jiang,, S. Rajyaguru,, G. Tavares,, C. Oshiro,, T. Hendricks,, K. Klumpp,, J. Symons,, M. F. Browner,, N. Cammack,, and I. Najera. 2006. Selection and characterization of replicon variants dually resistant to thumb- and palm-binding nonnucleoside polymerase inhibitors of the hepatitis C virus. J. Virol. 80:61466154.
123. Le Pogam, S.,, A. Seshaadri,, A. Kosaka,, S. Chiu,, H. Kang,, S. Hu,, S. Rajyaguru,, J. Symons,, N. Cammack,, and I. Najera. 2008. Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients. J. Antimicrob. Chemother. 61:12051216.
124. Liaw, Y. F.,, E. Gane,, N. Leung,, S. Zeuzem,, Y. Wang,, C. L. Lai,, E. J. Heathcote,, M. Manns,, N. Bzowej,, J. Niu,, S. H. Han,, S. G. Hwang,, Y. Cakaloglu,, M. J. Tong,, G. Papatheodoridis,, Y. Chen,, N. A. Brown,, E. Albanis,, K. Galil,, and N. V. Naoumov. 2009. 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 136:486495.
125. Liu, C. J.,, and J. H. Kao. 2008. Genetic variability of hepatitis B virus and response to antiviral therapy. Antivir. Ther. 13:613624.
126. Lok, A. S.,, and B. J. McMahon. 2009. Chronic hepatitis B: update 2009. Hepatology 50:661662.
127. Lok, A. S.,, F. Zoulim,, S. Locarnini,, A. Bartholomeusz,, M. G. Ghany,, J. M. Pawlotsky,, Y. F. Liaw,, M. Mizokami,, and C. Kuiken. 2007. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 46:254265.
128. Lu, J.,, S. G. Deeks,, R. Hoh,, G. Beatty,, B. A. Kuritzkes,, J. N. Martin,, and D. R. Kuritzkes. 2006. Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: results of a clonal analysis. J. Acquir. Immune Defic. Syndr. 43:6064.
129. Maag, D.,, C. Castro,, Z. Hong,, and C. E. Cameron. 2001. Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin. J. Biol. Chem. 276:4609446098.
130. Madruga, J. V.,, P. Cahn,, B. Grinsztejn,, R. Haubrich,, J. Lalezari,, A. Mills,, G. Pialoux,, T. Wilkin,, M. Peeters,, J. Vingerhoets,, G. de Smedt,, L. Leopold,, R. Trefiglio,, and B. Woodfall. 2007. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 370:2938.
131. Maeda, K.,, D. Das,, H. Ogata-Aoki,, H. Nakata,, T. Miyakawa,, Y. Tojo,, R. Norman,, Y. Takaoka,, J. Ding,, G. F. Arnold,, E. Arnold,, and H. Mitsuya. 2006. Structural and molecular interactions of CCR5 inhibitors with CCR5. J. Biol. Chem. 281:1268812698.
132. Marcellin, P.,, E. J. Heathcote,, M. Buti,, E. Gane,, R. A. de Man,, Z. Krastev,, G. Germanidis,, S. S. Lee,, R. Flisiak,, K. Kaita,, M. Manns,, I. Kotzev,, K. Tchernev,, P. Buggisch,, F. Weilert,, O. O. Kurdas,, M. L. Shiffman,, H. Trinh,, M. K. Washington,, J. Sorbel,, J. Anderson,, A. Snow-Lampart,, E. Mondou,, J. Quinn,, and F. Rousseau. 2008. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N. Engl. J. Med. 359:24422455.
133. Marcellin, P.,, G. K. Lau,, F. Bonino,, P. Farci,, S. Hadziyannis,, R. Jin,, Z. M. Lu,, T. Piratvisuth,, G. Germanidis,, C. Yurdaydin,, M. Diago,, S. Gurel,, M. Y. Lai,, P. Button,, and N. Pluck. 2004. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 351:12061217.
134. Martell, M.,, J. I. Esteban,, J. Quer,, J. Genesca,, A. Weiner,, R. Esteban,, J. Guardia,, and J. Gomez. 1992. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J. Virol. 66:32253229.
135. Masquelier, B.,, E. Race,, C. Tamalet,, D. Descamps,, J. Izopet,, C. Buffet-Janvresse,, A. Ruffault,, A. S. Mohammed,, J. Cottalorda,, A. Schmuck,, V. Calvez,, E. Dam,, H. Fleury,, and F. Brun-Vezinet. 2001. Genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 variants with insertions or deletions in the reverse transcriptase (RT): multicenter study of patients treated with RT inhibitors. Antimicrob. Agents Chemother. 45:18361842.
136. Matrosovich, M. N.,, T. Y. Matrosovich,, T. Gray,, N. A. Roberts,, and H. D. Klenk. 2004. Human and avian influenza viruses target different cell types in cultures of human airway epithelium. Proc. Natl. Acad. Sci. USA 101:46204624.
137. McColl, D. J.,, and X. Chen. 2010. Strand transfer inhibitors of HIV-1 integrase: bringing IN a new era of antiretroviral therapy. Antivir. Res. 85:101118.
138. McHutchison, J. G.,, G. T. Everson,, S. C. Gordon,, I. M. Jacobson,, M. Sulkowski,, R. Kauffman,, L. McNair,, J. Alam,, and A. J. Muir. 2009. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N. Engl. J. Med. 360:18271838.
139. McKimm-Breschkin, J.,, T. Trivedi,, A. Hampson,, A. Hay,, A. Klimov,, M. Tashiro,, F. Hayden,, and M. Zambon. 2003. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob. Agents Chemother. 47:22642272.
140. Meyer, P. R.,, S. E. Matsuura,, R. F. Schinazi,, A. G. So,, and W. A. Scott. 2000. Differential removal of thymidine nucleotide analogues from blocked DNA chains by human immunodeficiency virus reverse transcriptase in the presence of physiological concentrations of 29-deoxynucleoside triphosphates. Antimicrob. Agents Chemother. 44:34653472.
141. Miller, M. D.,, N. Margot,, B. Lu,, L. Zhong,, S. S. Chen,, A. Cheng,, and M. Wulfsohn. 2004. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. J. Infect. Dis. 189:837846.
142. Mink, M.,, S. M. Mosier,, S. Janumpalli,, D. Davison,, L. Jin,, T. Melby,, P. Sista,, J. Erickson,, D. Lambert,, S. A. Stanfield-Oakley,, M. Salgo,, N. Cammack,, T. Matthews,, and M. L. Greenberg. 2005. Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro. J. Virol. 79: 1244712454.
143. Molina, J. M.,, A. G. Marcelin,, J. Pavie,, L. Heripret,, C. M. De Boever,, M. Troccaz,, G. Leleu,, and V. Calvez. 2005. Didanosine in HIV-1-infected patients experiencing failure of antiretroviral therapy: a randomized placebo-controlled trial. J. Infect. Dis. 191:840847.
144. Monto, A. S.,, J. L. McKimm-Breschkin,, C. Macken,, A. W. Hampson,, A. Hay,, A. Klimov,, M. Tashiro,, R. G. Webster,, M. Aymard,, F. G. Hayden,, and M. Zambon. 2006. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob. Agents Chemother. 50:23952402.
145. Moore, J. P.,, and D. R. Kuritzkes. 2009. A piece de resistance: how HIV-1 escapes small molecule CCR5 inhibitors. Curr. Opin. HIV AIDS 4:118124.
146. Morfin, F.,, G. Souillet,, K. Bilger,, T. Ooka,, M. Aymard,, and D. Thouvenot. 2000. Genetic characterization of thymidine kinase from acyclovir-resistant and -susceptible herpes simplex virus type 1 isolated from bone marrow transplant recipients. J. Infect. Dis. 182:290293.
147. 147 Morfin, F.,, and D. Thouvenot. 2003. Herpes simplex virus resistance to antiviral drugs. J. Clin. Virol. 26:2937.
148. Morfin, F.,, D. Thouvenot,, M. De Turenne-Tessier,, B. Lina,, M. Aymard,, and T. Ooka. 1999. Phenotypic and genetic characterization of thymidine kinase from clinical strains of varicella-zoster virus resistant to acyclovir. Antimicrob. Agents Chemother. 43:24122416.
149. Moucari, R.,, A. Korevaar,, O. Lada,, M. Martinot-Peignoux,, N. Boyer,, V. Mackiewicz,, A. Dauvergne,, A. C. Cardoso,, T. Asselah,, M. H. Nicolas-Chanoine,, M. Vidaud,, D. Valla,, P. Bedossa,, and P. Marcellin. 2009. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study. J. Hepatol. 50:10841092.
150. Moucari, R.,, M. Martinot-Peignoux,, V. Mackiewicz,, N. Boyer,, M. P. Ripault,, C. Castelnau,, L. Leclere,, A. Dauvergne,, D. Valla,, M. Vidaud,, M. H. Nicolas-Chanoine,, and P. Marcellin. 2009. Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-alpha2a. Antivir. Ther. 14:11831188.
151. Nelson, M. I.,, L. Simonsen,, C. Viboud,, M. A. Miller,, and E. C. Holmes. 2009. The origin and global emergence of adamantane resistant A/H3N2 influenza viruses. Virology 388:270278.
152. Nikkels, A. F.,, R. Snoeck,, B. Rentier,, and G. E. Pierard. 1999. Chronic verrucous varicella zoster virus skin lesions: clinical, histological, molecular and therapeutic aspects. Clin. Exp. Dermatol. 24:346353.
153. Nowak, M. A.,, S. Bonhoeffer,, A. M. Hill,, R. Boehme,, H. C. Thomas,, and H. McDade. 1996. Viral dynamics in hepatitis B virus infection. Proc. Natl. Acad. Sci. USA 93:43984402.
154. Okomo-Adhiambo, M.,, H. T. Nguyen,, K. Sleeman,, T. G. Sheu,, V. M. Deyde,, R. J. Garten,, X. Xu,, M. W. Shaw,, A. I. Klimov,, and L. V. Gubareva. 2010. Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses. Antivir. Res. 85:381388.
155. Ono, S. K.,, N. Kato,, Y. Shiratori,, J. Kato,, T. Goto,, R. F. Schinazi,, F. J. Carrilho,, and M. Omata. 2001. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J. Clin. Investig. 107:449455.
156. Ormrod, D.,, and K. Goa. 2000. Valaciclovir: a review of its use in the management of herpes zoster. Drugs 59:13171340.
157. Parikh, U. M.,, D. L. Koontz,, C. K. Chu,, R. F. Schinazi,, and J. W. Mellors. 2005. In vitro activity of structurally diverse nucleoside analogs against human immunodeficiency virus type 1 with the K65R mutation in reverse transcriptase. Antimicrob. Agents Chemother. 49:11391144.
158. Parkin, N. T.,, N. S. Hellmann,, J. M. Whitcomb,, L. Kiss,, C. Chappey,, and C. J. Petropoulos. 2004. Natural variation of drug susceptibility in wild-type HIV-1. Antimicrob. Agents Chemother. 48:437443.
159. Parkin, N. T.,, and J. M. Schapiro. 2004. Antiretroviral drug resistance in non-subtype B HIV-1, HIV-2 and SIV. Antivir. Ther. 9:312.
160. Pauwels, F.,, W. Mostmans,, L. M. Quirynen,, L. van der Helm,, C. W. Boutton,, A. S. Rueff,, E. Cleiren,, P. Raboisson,, D. Surleraux,, O. Nyanguile,, and K. A. Simmen. 2007. Bindingsite identification and genotypic profiling of hepatitis C virus polymerase inhibitors. J. Virol. 81:69096919.
161. Penin, F.,, J. Dubuisson,, F. A. Rey,, D. Moradpour,, and J. M. Pawlotsky. 2004. Structural biology of hepatitis C virus. Hepatology 39:519.
162. Peters, M. G.,, H. Hann Hw,, P. Martin,, E. J. Heathcote,, P. Buggisch,, R. Rubin,, M. Bourliere,, K. Kowdley,, C. Trepo,, D. Gray Df,, M. Sullivan,, K. Kleber,, R. Ebrahimi,, S. Xiong,, and C. L. Brosgart. 2004. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudineresistant chronic hepatitis B. Gastroenterology 126:91101.
163. Piccolo, P.,, I. Lenci,, L. Demelia,, F. Bandiera,, M. R. Piras,, G. Antonucci,, L. Nosotti,, T. Mari,, A. De Santis,, M. L. Ponti,, O. Sorbello,, F. Iacomi,, and M. Angelico. 2009. A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B. Antivir. Ther. 14:11651174.
164. Pielak, R. M.,, J. R. Schnell,, and J. J. Chou. 2009. Mechanism of drug inhibition and drug resistance of influenza A M2 channel. Proc. Natl. Acad. Sci. USA 106:73797384.
165. Pockros, P. J.,, D. Nelson,, E. Godofsky,, M. Rodriguez- Torres,, G. T. Everson,, M. W. Fried,, R. Ghalib,, S. Harrison,, L. Nyberg,, M. L. Shiffman,, I. Najera,, A. Chan,, and G. Hill. 2008. R1626 plus peginterferon alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin. Hepatology 48:385397.
166. Prichard, M. N. 2009. Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir. Rev. Med. Virol. 19:215229.
167. Rapti, I.,, E. Dimou,, P. Mitsoula,, and S. J. Hadziyannis. 2007. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 45:307313.
168. Reece, P. A. 2007. Neuraminidase inhibitor resistance in influenza viruses. J. Med. Virol. 79:15771586.
169. Rhee, S. Y.,, J. Taylor,, G. Wadhera,, A. Ben-Hur,, D. L. Brutlag,, and R. W. Shafer. 2006. Genotypic predictors of human immunodeficiency virus type 1 drug resistance. Proc. Natl. Acad. Sci. USA 103:1735517360.
170. Saijo, M.,, T. Suzutani,, K. Itoh,, Y. Hirano,, K. Murono,, M. Nagamine,, K. Mizuta,, M. Niikura,, and S. Morikawa. 1999. Nucleotide sequence of thymidine kinase gene of sequential acyclovir-resistant herpes simplex virus type 1 isolates recovered from a child with Wiskott-Aldrich syndrome: evidence for reactivation of acyclovir-resistant herpes simplex virus. J. Med. Virol. 58:387393.
171. Saldanha, J.,, W. Gerlich,, N. Lelie,, P. Dawson,, K. Heermann,, and A. Heath. 2001. An international collaborative study to establish a World Health Organization international standard for hepatitis B virus DNA nucleic acid amplification techniques. Vox Sang. 80:6371.
172. Santantonio, T.,, M. Fasano,, S. Durantel,, L. Barraud,, M. Heichen,, A. Guastadisegni,, G. Pastore,, and F. Zoulim. 2009. Adefovir dipivoxil resistance patterns in patients with lamivudine-resistant chronic hepatitis B. Antivir. Ther. 14:557565.
173. Sarafianos, S. G.,, K. Das,, S. H. Hughes,, and E. Arnold. 2004. Taking aim at a moving target: designing drugs to inhibit drug-resistant HIV-1 reverse transcriptases. Curr. Opin. Struct. Biol. 14:716730.
174. Sarisky, R. T.,, M. R. Quail,, P. E. Clark,, T. T. Nguyen,, W. S. Halsey,, R. J. Wittrock,, J. O’Leary Bartus,, M. M. Van Horn,, G. M. Sathe,, S. Van Horn,, M. D. Kelly,, T. H. Bacon,, and J. J. Leary. 2001. Characterization of herpes simplex viruses selected in culture for resistance to penciclovir or acyclovir. J. Virol. 75:17611769.
175. Sarrazin, C.,, J. Hong,, S. Lim,, Z. Qin,, S. Susser,, B. Bradford,, S. Porter, et al. 2009. Incidence of virologic escape observed during ITMN-191 (R7227) monotherapy is genotpe dependent, associated with specific NS3 substitution, and suppressed upon combination with peginterferon alfa-2A/ribavirin. J. Hepatol. 50(Suppl. 1):S350.
176. Sarrazin, C.,, T. L. Kieffer,, D. Bartels,, B. Hanzelka,, U. Muh,, M. Welker,, D. Wincheringer,, Y. Zhou,, H. M. Chu,, C. Lin,, C. Weegink,, H. Reesink,, S. Zeuzem,, and A. D. Kwong. 2007. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 132:17671777.
177. Sarrazin, C.,, and S. Zeuzem. 2010. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 138:447462.
178. Scott, G. M.,, A. Weinberg,, W. D. Rawlinson,, and S. Chou. 2007. Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates. Antimicrob. Agents Chemother. 51:8994.
179. Shafer, R. W.,, M. J. Kozal,, M. A. Winters,, A. K. Iversen,, D. A. Katzenstein,, M. V. Ragni,, W. A. Meyer,, P. Gupta,, S. Rasheed,, R. Coombs,, and T. C. Merigan. 1994. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. J. Infect. Dis. 169:722729.
180. Shahriar, R.,, S. Y. Rhee,, T. F. Liu,, W. J. Fessel,, A. Scarsella,, W. Towner,, S. P. Holmes,, A. R. Zolopa,, and R. W. Shafer. 2009. Nonpolymorphic human immunodeficiency virus type 1 protease and reverse transcriptase treatment-selected mutations. Antimicrob. Agents Chemother. 53:48694878.
181. Sherman, M.,, C. Yurdaydin,, H. Simsek,, M. Silva,, Y. F. Liaw,, V. K. Rustgi,, H. Sette,, N. Tsai,,